NASDAQ:OVID Ovid Therapeutics (OVID) Stock Price, News & Analysis $0.28 -0.02 (-6.95%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$0.29 +0.01 (+3.57%) As of 05/30/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Ovid Therapeutics Stock (NASDAQ:OVID) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Ovid Therapeutics alerts:Sign Up Key Stats Today's Range$0.27▼$0.3050-Day Range$0.26▼$0.4152-Week Range$0.24▼$3.31Volume789,971 shsAverage Volume478,917 shsMarket Capitalization$19.91 millionP/E RatioN/ADividend YieldN/APrice Target$2.78Consensus RatingBuy Company OverviewOvid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.Read More… Ovid Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks80th Percentile Overall ScoreOVID MarketRank™: Ovid Therapeutics scored higher than 80% of companies evaluated by MarketBeat, and ranked 200th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingOvid Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageOvid Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Ovid Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Ovid Therapeutics are expected to decrease in the coming year, from ($0.40) to ($0.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ovid Therapeutics is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ovid Therapeutics is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOvid Therapeutics has a P/B Ratio of 0.23. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Ovid Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.74% of the float of Ovid Therapeutics has been sold short.Short Interest Ratio / Days to CoverOvid Therapeutics has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in Ovid Therapeutics has recently increased by 21.64%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOvid Therapeutics does not currently pay a dividend.Dividend GrowthOvid Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-0.85 Percentage of Shares Shorted2.74% of the float of Ovid Therapeutics has been sold short.Short Interest Ratio / Days to CoverOvid Therapeutics has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in Ovid Therapeutics has recently increased by 21.64%, indicating that investor sentiment is decreasing significantly. News and Social Media1.4 / 5News Sentiment-0.42 News SentimentOvid Therapeutics has a news sentiment score of -0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Ovid Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for OVID on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows1 people have added Ovid Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Ovid Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders13.10% of the stock of Ovid Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions72.24% of the stock of Ovid Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ovid Therapeutics' insider trading history. Receive OVID Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ovid Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address OVID Stock News HeadlinesQ2 EPS Forecast for Ovid Therapeutics Decreased by AnalystMay 30 at 1:18 AM | americanbankingnews.comHC Wainwright Issues Pessimistic Forecast for Ovid Therapeutics (NASDAQ:OVID) Stock PriceMay 29 at 1:15 AM | americanbankingnews.comEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.May 31, 2025 | Timothy Sykes (Ad)Ovid Therapeutics Inc. (NASDAQ:OVID) Receives Consensus Recommendation of "Buy" from AnalystsMay 22, 2025 | americanbankingnews.comOvid Therapeutics Reports Business Updates and First Quarter 2025 Financial ResultsMay 13, 2025 | globenewswire.comOvid Police Chief, city accused of civil rights violationsApril 24, 2025 | msn.comOvid Therapeutics (OVID) Receives a Buy from TD CowenApril 23, 2025 | theglobeandmail.comOvid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare ConferenceApril 2, 2025 | markets.businessinsider.comSee More Headlines OVID Stock Analysis - Frequently Asked Questions How have OVID shares performed this year? Ovid Therapeutics' stock was trading at $0.9337 at the start of the year. Since then, OVID shares have decreased by 70.0% and is now trading at $0.28. View the best growth stocks for 2025 here. How were Ovid Therapeutics' earnings last quarter? Ovid Therapeutics Inc. (NASDAQ:OVID) issued its earnings results on Tuesday, May, 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.14). The company had revenue of $0.13 million for the quarter, compared to the consensus estimate of $0.03 million. Ovid Therapeutics had a negative net margin of 5,142.56% and a negative trailing twelve-month return on equity of 39.24%. When did Ovid Therapeutics IPO? Ovid Therapeutics (OVID) raised $80 million in an IPO on Friday, May 5th 2017. The company issued 5,000,000 shares at $15.00-$17.00 per share. Citigroup and Cowen and Company acted as the underwriters for the IPO and William Blair and JMP Securities were co-managers. Who are Ovid Therapeutics' major shareholders? Ovid Therapeutics' top institutional investors include Acadian Asset Management LLC (2.94%), Adage Capital Partners GP L.L.C. (1.62%), Affinity Asset Advisors LLC (0.94%) and Assenagon Asset Management S.A. (0.79%). Insiders that own company stock include Jeremy M Levin, Margaret A Alexander and Jason Tardio. View institutional ownership trends. How do I buy shares of Ovid Therapeutics? Shares of OVID stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ovid Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ovid Therapeutics investors own include Plug Power (PLUG), Alamos Gold (AGI), FuelCell Energy (FCEL), KALA BIO (KALA), Lipocine (LPCN), Fortress Biotech (FBIO) and Workhorse Group (WKHS). Company Calendar Last Earnings5/13/2025Today5/31/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:OVID CIK1636651 Webwww.ovidrx.com Phone(646) 661-7661FaxN/AEmployees60Year Founded2014Price Target and Rating Average Stock Price Target$2.78 High Stock Price Target$4.00 Low Stock Price Target$1.20 Potential Upside/Downside+894.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$52.34 million Net Margins-5,142.56% Pretax Margin-5,142.56% Return on Equity-39.24% Return on Assets-26.19% Debt Debt-to-Equity Ratio0.18 Current Ratio5.66 Quick Ratio5.66 Sales & Book Value Annual Sales$548,000.00 Price / Sales36.33 Cash FlowN/A Price / Cash FlowN/A Book Value$1.24 per share Price / Book0.23Miscellaneous Outstanding Shares71,110,000Free Float61,566,000Market Cap$19.91 million OptionableOptionable Beta0.27 Social Links The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:OVID) was last updated on 5/31/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ovid Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ovid Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.